Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy

被引:354
作者
Choi, S. [1 ]
Myers, J. N. [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
关键词
oral squamous cell carcinoma; multistep carcinogenesis; oncogene; tumor suppressor gene; molecular targeted therapy;
D O I
10.1177/154405910808700104
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The development of oral squamous cell carcinoma (OSCC) is a multistep process requiring the accumulation of multiple genetic alterations, influenced by a patient's genetic predisposition as well as by environmental influences, including tobacco, alcohol, chronic inflammation, and viral infection. Tumorigenic genetic alterations consist of two major types: tumor suppressor genes, which promote tumor development when inactivated; and oncogenes, which promote tumor development when activated. Tumor suppressor genes can be inactivated through genetic events such as mutation, loss of heterozygosity, or deletion, or by epigenetic modifications such as DNA methylation or chromatin remodeling. Oncogenes can be activated through overexpression due to gene amplification, increased transcription, or changes in structure due to mutations that lead to increased transforming activity. This review focuses on the molecular mechanisms of oral carcinogenesis and the use of biologic therapy to specifically target molecules altered in OSCC. The rapid progress that has been made in our understanding of the molecular alterations contributing to the development of OSCC is leading to improvements in the early diagnosis of tumors and the refinement of biologic treatments individualized to the specific characteristics of a patient's tumor.
引用
收藏
页码:14 / 32
页数:19
相关论文
共 313 条
[31]  
BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
[32]  
2-6
[33]   The role of STATs in transcriptional control and their impact on cellular function [J].
Bromberg, J ;
Darnell, JE .
ONCOGENE, 2000, 19 (21) :2468-2473
[34]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[35]  
BROWN PH, 1993, ONCOGENE, V8, P877
[36]   Farnesyltransferase inhibitors as radiation sensitizers [J].
Brunner, TB ;
Gupta, AK ;
Shi, Y ;
Hahn, SM ;
Muschel, RJ ;
Mckenna, WG ;
Bernhard, EJ .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (07) :569-576
[37]   Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors [J].
Buck, Elizabeth ;
Eyzaguirre, Alexandra ;
Brown, Eric ;
Petti, Filippo ;
McCormack, Siobhan ;
Haley, John D. ;
Iwata, Kenneth K. ;
Gibson, Neil W. ;
Griffin, Graeme .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2676-2684
[38]  
CAAMANO J, 1993, AM J PATHOL, V142, P1131
[39]   p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma:: A prospective series [J].
Cabelguenne, A ;
Blons, H ;
de Waziers, I ;
Carnot, F ;
Houllier, AM ;
Soussi, T ;
Brasnu, D ;
Beaune, P ;
Luccourreye, O ;
Laurent-Puig, P .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1465-1473
[40]  
Califano J, 1996, CANCER RES, V56, P2488